Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial

Autor:	Nolwenn Hall, Clotilde Allavena, Christine Katlama, Alexandra Jobert, Jean-Michel Molina, Eric Cua, Firouzé Bani-Sadr, Laurent Hocqueloux, Claudine Duvivier, Dominique Merrien, Hitoto Hikombo, Elisabeth André-Garnier, Aurélie Gaultier, François Raffi, the QDISS Study Group
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	HIV-1 infection Raltegravir Once daily Integrase inhibitor Maintenance Switch Immunologic diseases. Allergy RC581-607
Zdroj:	AIDS Research and Therapy, Vol 19, Iss 1, Pp 1-6 (2022)
Druh dokumentu:	article
ISSN:	1742-6405
DOI:	10.1186/s12981-022-00428-5
Popis:	Abstract Background Raltegravir (RAL) has favorable tolerability and safety profile, with few and manageable drug interactions. The use of RAL 1200 mg once daily (qd) for first-line therapy is well established. We assessed efficacy and safety of RAL 1200 mg qd, as part of triple combined antiretroviral therapy (cART), for maintenance strategy. Methods The QDISS trial (NCT03195452) was a 48-week multicenter, single-arm, open-label study designed to evaluate the ability of 2 NRTIs + RAL 1200 mg qd to maintain virological suppression in HIV-1 infected subjects on a stable cART with 2 NRTIs and a third agent for at least 6 months. The primary endpoint was the proportion of participants with HIV-1 RNA
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/92db89510b02477094df275432b25b0c Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.